Literature DB >> 14742314

An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation.

Masataka Kagawa1, Tetsuro Sano, Naoto Ishibashi, Manabu Hashimoto, Masataka Okuno, Hisataka Moriwaki, Rikako Suzuki, Hiroyuki Kohno, Takuji Tanaka.   

Abstract

The present study was designed to determine the effects of NIK-333, a synthetic acyclic retinoid, on N-diethylnitrosamine (DEN)-induced hepatocarcinogenesis in male F344 rats. Animals were given DEN dissolved in drinking water at a concentration of 40 p.p.m. for 5 weeks and then provided with drinking water free of DEN for 15 weeks to induce hepatocellular neoplasms. NIK-333 was administered orally (once a day) to rats at doses of 10, 40 and 80 mg/kg body wt for 14 weeks, starting 1 week after the completion of administration of DEN. At 20 weeks after the start of DEN administration, histopathological evaluation was carried out on all animals. The effects of NIK-333 on the cell proliferation activity of non-tumorous areas and liver tumor cells and the immunohistochemical expression of transforming growth factor-alpha (TGF-alpha) were also evaluated. NIK-333 at 40 and 80 mg/kg body wt significantly inhibited hepatocarcinogenesis (P < 0.05). In addition, NIK-333 at the same doses decreased DEN-induced overexpression of TGF-alpha in hepatocellular neoplasms (adenomas and carcinomas) and their surrounding tissue. Furthermore, NIK-333 significantly inhibited cell proliferation activity in the lesions and in non-tumorous areas (P < 0.01). Our results suggest that NIK-333 inhibits DEN-induced hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742314     DOI: 10.1093/carcin/bgh093

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

Review 1.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 3.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Hepatic metabolism of retinoids and disease associations.

Authors:  Yohei Shirakami; Seung-Ah Lee; Robin D Clugston; William S Blaner
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 5.  Retinoids and rexinoids in cancer prevention: from laboratory to clinic.

Authors:  Iván P Uray; Ethan Dmitrovsky; Powel H Brown
Journal:  Semin Oncol       Date:  2015-09-25       Impact factor: 4.929

6.  Transplanted bone marrow stromal cells are not cellular origin of hepatocellular carcinomas in a mouse model of carcinogenesis.

Authors:  Jin-Fang Zheng; Li-Jian Liang
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 7.  Retinoids: novel immunomodulators and tumour-suppressive agents?

Authors:  M R Carratù; C Marasco; G Mangialardi; A Vacca
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

8.  Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.

Authors:  Masahito Shimizu; Yohei Shirakami; Kenji Imai; Koji Takai; Hisataka Moriwaki
Journal:  J Carcinog       Date:  2012-08-30

9.  Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells.

Authors:  Hideki Tatsukawa; Tetsuro Sano; Yayoi Fukaya; Naoto Ishibashi; Makiko Watanabe; Masataka Okuno; Hisataka Moriwaki; Soichi Kojima
Journal:  Mol Cancer       Date:  2011-01-09       Impact factor: 27.401

10.  Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma.

Authors:  Masao Honda; Taro Yamashita; Tatsuya Yamashita; Kuniaki Arai; Yoshio Sakai; Akito Sakai; Mikiko Nakamura; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  BMC Cancer       Date:  2013-04-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.